Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03672253 | CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma | unknown | Phase 1 | 20 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03674463 | LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | unknown | Phase 1 | 10 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 4 | Dec 11, 2018 | clinicaltrials |
| NCT03767725 | Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | unknown | Phase 1 | 10 | Shenzhen Second People's HospitalOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT03767751 | A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT01306643 | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | completed | Phase 1 / Phase 2 | 18 | Gilead SciencesINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 8, 2018 | clinicaltrials |
| NCT00790842 | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction(PrE1003) | terminated | Phase 1 / Phase 2 | 63 | PrECOG, LLC.OTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01342289 | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | completed | Phase 1 | 127 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03706547 | Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | unknown | Phase 1 | 20 | Peng LiuOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma(rev/abraxane) | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT00231166 | Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 11, 2018 | clinicaltrials |
| NCT00024466 | Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01355705 | Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 14 | Michaela LiedtkeOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01672736 | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 19 | University Health Network, TorontoOTHER | 2 | Sep 13, 2018 | clinicaltrials |
| NCT02462525 | Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 74 | AbbVieINDUSTRY | 4 | Sep 13, 2018 | clinicaltrials |
| NCT01950273 | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | completed | Phase 1 | 95 | Boehringer IngelheimINDUSTRY | 13 | Sep 5, 2018 | clinicaltrials |
| NCT01272466 | Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Herlev HospitalOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 31, 2018 | clinicaltrials |
| NCT01707264 | Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 69 | Prothena Biosciences Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00901615 | Lenalidomide and R-CHOP in B-cell Lymphoma(R2CHOP-1) | completed | Phase 1 / Phase 2 | 108 | Lymphoma Study AssociationOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT02030483 | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma(PD + RD) | terminated | Phase 1 | 9 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT02702141 | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00701103 | Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | completed | Phase 1 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT01428492 | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma(PKB115125) | completed | Phase 1 | 90 | NovartisINDUSTRY | 5 | Aug 8, 2018 | clinicaltrials |
| NCT01690143 | Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01777243 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02071888 | Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | completed | Phase 1 | 25 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01484626 | Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma(BVRD) | terminated | Phase 1 / Phase 2 | 3 | Loyola UniversityOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT00001830 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | completed | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01563302 | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers | completed | Phase 1 / Phase 2 | 64 | Ionis Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 25, 2018 | clinicaltrials |
| NCT01979276 | Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma(Romi Poma) | terminated | Phase 1 / Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02203825 | Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | completed | Phase 1 | 12 | Celyad Oncology SAINDUSTRY | 1 | Jun 1, 2018 | clinicaltrials |
| NCT01936090 | Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 | 11 | Mayo ClinicOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT03023527 | Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma | terminated | Phase 1 | 6 | PETHEMA FoundationOTHER | 1 | May 23, 2018 | clinicaltrials |
| NCT01711528 | Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | May 11, 2018 | clinicaltrials |
| NCT02372240 | A Study of VLX1570 and Dexamethasone in Myeloma Patients | terminated | Phase 1 / Phase 2 | 15 | Vivolux ABINDUSTRY | 1 | May 11, 2018 | clinicaltrials |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | terminated | Phase 1 / Phase 2 | 8 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00952237 | Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF | completed | Phase 1 | 13 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02216890 | Safety Study of SGN-CD70A in Cancer Patients | completed | Phase 1 | 38 | Seagen Inc.INDUSTRY | 1 | Apr 19, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01729806 | Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma | completed | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01832922 | BR in Patients With CLL With Comorbidities and/or Renal Dysfunction | completed | Phase 1 | 8 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00909948 | Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant(RLI) | terminated | Phase 1 | 7 | Massachusetts General HospitalOTHER | 1 | Mar 29, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 14, 2018source: clinicaltrials